RCS - Spexis AG - Spexis to present at BioEquity Europe 2022

Spexis AGAnnouncement

12/05/2022 08:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220512:nRSL2418La&default-theme=true

RNS Number : 2418L  Spexis AG  12 May 2022

Spexis to present at BioEquity Europe 2022
 Spexis AG / Key word(s): Conference

Spexis to present at BioEquity Europe 2022

12.05.2022 / 07:30 CET

 Allschwil, Switzerland, May 12, 2022

 Spexis to present at BioEquity Europe 2022

 Spexis AG (SIX: SPEX) today announced that that the company will present at
 BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of
 Spexis, will provide an overview of the company and its pipeline and will be
 available to participate in one-on-one meetings with investors who are
 registered to attend the conference.

 The presentation is now available to conference registrants. For more
 information on the conference, visit the BioEquity website
 (https://conferences.biocentury.com/bioequity-europe) .

For further information please contact:

For Investors:                                          For Media:

Hernan Levett
 Dr. Stephan Feldhaus

Chief Financial Officer
 Feldhaus & Partner

Spexis AG.
 +41 79 865 92 56
 +41 61 567 16 00                                        feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
 IR@spexisbio.com (mailto:IR@spexisbio.com)

Raimund Gabriel
 Dr. Brigitte Keller/Laurie Doyle

MC Services
 MC Services
 spexis@mc-services.eu (mailto:spexis@mc-services.eu)    spexis@mc-services.eu (mailto:spexis@mc-services.eu)

Ph: +49 89 210 228 0
 Europe: +49 89 210 228 0

 U.S.: +1 339 832 0752

 

 About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
 Switzerland, focused on rare diseases and oncology. The current pipeline of
 the company is a combination of two legacy companies, Polyphor AG and
 EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
 company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
 under the symbol SIX:SPEX. For further information please
 visit: www.spexisbio.com (https://spexisbio.com/) .

 Disclaimer

This press release contains forward-looking statements which are based on
 current assumptions and forecasts of Spexis management. Known and unknown
 risks, uncertainties, and other factors could lead to material differences
 between the forward-looking statements made here and the actual development,
 in particular Spexis' results, financial situation, and performance. Readers
 are cautioned not to put undue reliance on forward-looking statements, which
 speak only as of the date of this communication. Spexis disclaims any
 intention or obligation to update and revise any forward-looking statements,
 whether as a result of new information, future events or otherwise.

End of Media Release

 

About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please
visit: www.spexisbio.com (https://spexisbio.com/) .

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only as of the date of this communication. Spexis disclaims any
intention or obligation to update and revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

 

End of Media Release

 Language:     English
 Company:      Spexis AG
               Hegenheimermattweg 125
               4123 Allschwil
               Switzerland
 Phone:        +41 61 567 1600
 Fax:          +41 61 567 1601
 E-mail:       info@spexisbio.com
 Internet:     www.spexisbio.com
 ISIN:         CH0106213793
 Valor:        SPEX
 Listed:       SIX Swiss Exchange
 EQS News ID:  1350291

 

 End of News  EQS News Service

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUUVVRUVUVARR